Adrenaline in treatment of Anaphylactic Shock- pharmacological basis; Adrenaline therapeutic uses with justification, with pharmacological basis,dose and route of administration; Vasopressor Agents - enumerate four, Adrenaline contraindicated in Hypotensive Shock-explain why; Adrenaline-pharmacological actions, therapeutic uses, adverse effects; precautions while administering; Classify Adrenergic Drugs uses, adverse effect ; Drugs used in Glaucoma - mention, MOA detail ; Beta Adrenergic Blockers - classify, Therapeutic Uses - enumerate, Non-Cardiovascular Uses; Propranolol and Atenolol - eight clinically relevant differences; Alpha Adrenergic Blocker - uses, adverse effect; Atenolol and Propranolol - compare and contrast ; Propranolol - therapeutic uses with rationale; Drugs used in Glaucoma- classify, MOA, adverse effects,pharmacological rationale for each drug; Beta Blockers- classify, cardiac, non-cardiac uses, examples with rationale,therapeutic uses; For 2nd yr mbbs pharmacology refer kd tripathi all answer in details for 10 m
| # | Topic | Location Above |
|---|---|---|
| 1 | Adrenaline in Anaphylactic Shock - pharmacological basis | Section 1 |
| 2 | Adrenaline - therapeutic uses, justification, dose, route | Section 2B |
| 3 | Vasopressor agents - enumerate four | Section 3 |
| 4 | Adrenaline contraindicated in hypotensive shock - why | Section 4 |
| 5 | Adrenaline - actions, uses, adverse effects, precautions | Section 2 (A, B, C, D) |
| 6 | Adrenergic drugs - classify, uses, adverse effects | Section 5 |
| 7 | Drugs in Glaucoma - mention, MOA detail | Section 6 |
| 8 | Beta-adrenergic blockers - classify, therapeutic uses, non-cardiovascular | Section 7 |
| 9 | Propranolol vs Atenolol - 8 clinically relevant differences | Section 8 |
| 10 | Alpha-adrenergic blockers - uses, adverse effects | Section 9 |
| 11 | Atenolol and Propranolol - compare and contrast | Section 8 (same table) |
| 12 | Propranolol - therapeutic uses with rationale | Covered in Sections 7 + 8 |
| 13 | Drugs in Glaucoma - classify, MOA, ADRs, pharmacological rationale | Section 6 (detailed) |